Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jemermed.2020.03.029 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hot Phases Cardiomyopathy: Pathophysiology, Diagnostic Challenges, and Emerging Therapies.
Curr Cardiol Rep
January 2025
Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), European Reference Network for Rare, University of Trieste, Via P. Valdoni 7, 34100, Trieste, Italy.
Purpose Of Review: Hot phases are a challenging clinical presentation in arrhythmogenic cardiomyopathy (ACM), marked by acute chest pain and elevated cardiac troponins in the absence of obstructive coronary disease. These episodes manifest as myocarditis and primarily affect young patients, contributing to a heightened risk of life-threatening arrhythmias and potential disease progression. This review aims to synthesize recent research on the pathophysiology, diagnostic challenges, and therapeutic management of hot phases in ACM.
View Article and Find Full Text PDFDesmoplakin Cardiomyopathy: Role of Inflammation and Potential Role of Disease-Modifying Therapies.
Curr Cardiol Rep
January 2025
Department of Internal Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA.
Purpose Of Review: To summarize the available data on the use of immunosuppression therapies for the management of hot phases of disease and recurrent myocarditis in patients with desmoplakin cardiomyopathy (DSP-CMP).
Recent Findings: Occurrence of myocarditis episodes has been associated with worsening of outcomes in DSP-CMP. Multiple case reports and small case series have described potential benefit in using anti-inflammatory and immunosuppressive medications for the treatment of those episodes.
Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function.
Cardiooncology
January 2025
Division of Cardiology, Tel Aviv Sourasky medical Center, Tel Aviv, Israel.
Aims: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment outcomes. However, the response varies across different populations, and their use may lead to life-threatening cardiovascular (CV) events. While pre-treatment reduced left ventricular ejection fraction (LVEF) is considered a marker for high-risk cardiotoxicity and a contraindication for anthracycline and HER2-targeted therapies, there is limited evidence on the safety and efficacy of ICIs therapy in patients presenting with pre-treatment reduced LVEF.
View Article and Find Full Text PDFAssessing outcomes of acute myocarditis in Saudi Arabia: A retrospective tertiary center experience.
Saudi Med J
January 2025
From the College of Medicine (Bin Abdu, Assiri, Altasan, Alghamdi, Alshelawy, Alqahtani, Aljabr, Alnahdi, Alhamzani, Alghamdi, Alzahrani, Alshahrani, Alzahrani, Alshalawi), King Saud Bin Abdulaziz University for Health Sciences; from the Department of Medicine (Bin Abdu, Assiri, Altasan, Alghamdi, Alshelawy, Alqahtani, Aljabr, Alnahdi, Alhamzani, Alghamdi, Alzahrani, Alshahrani, Alzahrani, Alshalawi), King Abdullah International Medical Research Center; and from the Emergency Department (Alshalawi), King Abdulaziz Medical City Riyadh, Kingdom of Saudi Arabia.
Objectives: To assess the clinical course and long-term outcomes of complicated and uncomplicated AM in Saudi Arabia. Acute myocarditis (AM) can have different presentations and outcomes based on different factors, one of which is left ventricular ejection fraction (LVEF).
Methods: Data from 382 patients with suspected AM, admitted between January 2016 and October 2023, were reviewed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!